$LIMN 8-K SEC Filings

Filed On	Filing
29 Sep 2026	8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Regulation FD Disclosure FULLERTON, Calif., September 29, 2026 – Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid price rule.
18 Aug 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Material Modification to Rights of Security Holders +2 more
04 Aug 2026	8-K: Submission of Matters to a Vote of Security Holders
30 Jul 2026	8-K: Other Events
24 Jul 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events
06 Jul 2026	8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
03 Jun 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
27 May 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
20 May 2026	8-K: Entry into a Material Definitive Agreement
04 Mar 2026	8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
18 Feb 2026	8-K: Entry into a Material Definitive Agreement; Other Events
09 Feb 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
26 Jan 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
25 Nov 2025	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
25 Aug 2025	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
14 Aug 2025	8-K: Regulation FD Disclosure
17 Jul 2025	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
11 Jul 2025	8-K: Departure/Election of Directors or Officers; Compensation
03 Jul 2025	8-K: Other Events
24 Jun 2025	8-K: Regulation FD Disclosure

Comments